InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,260.30
(
0.27%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: JJM760 post# 126415

Sunday, 09/11/2011 2:55:27 PM

Sunday, September 11, 2011 2:55:27 PM

Post# of 252302

Wouldn't you think that the Rida results, while not spectacular, are probably good enough for approval?



I think if Tarceva received approval for maintenance therapy in NSCLC based on a modest improvement in outcomes, then ridaforolimus should be approved for sarcoma.

Nevertheless, I've mentioned on the ARIA board before that I am nervous about its approval chances. I'm not excited about ridaforolimus' commercial potential for sarcoma either. Ponatinib is undoubtedly ARIA's crown jewel. For me, any success with ridaforolimus would be a bonus.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up